Earnings summaries and quarterly performance for Lineage Cell Therapeutics.
Executive leadership at Lineage Cell Therapeutics.
Board of directors at Lineage Cell Therapeutics.
Research analysts who have asked questions during Lineage Cell Therapeutics earnings calls.
Jack Allen
Robert W. Baird & Co.
4 questions for LCTX
Also covers: ALLO, BLUE, CLLS +6 more
Michael Okunewitch
Maxim Group
4 questions for LCTX
Also covers: BLFS, BLTE, BNGO +11 more
GL
Gum-Ming Lowe
Craig-Hallum Capital Group LLC
3 questions for LCTX
Also covers: CRDF, SKYE
Joseph Pantginis
H.C. Wainwright & Co.
3 questions for LCTX
Also covers: ARMP, BCDA, BLRX +15 more
Sean McCutcheon
Raymond James
2 questions for LCTX
Also covers: BMY, CMPX, CRIS +6 more
WW
William Wood
B. Riley Securities
2 questions for LCTX
Also covers: ALT, GUTS, IMUX +3 more
KK
Kevin Kuo
B. Riley Securities
1 question for LCTX
Kristen Kluska
Cantor Fitzgerald
1 question for LCTX
Also covers: ABEO, ADMA, AQST +24 more
LD
Lucy De Yang
Raymond James
1 question for LCTX
Mayank Mamtani
B. Riley Securities
1 question for LCTX
Also covers: AGEN, ALT, ARWR +18 more
Recent press releases and 8-K filings for LCTX.
Lineage Cell Therapeutics Highlights 2025 Achievements and 2026 Outlook
LCTX
New Projects/Investments
Guidance Update
- Lineage Cell Therapeutics issued a letter to stockholders detailing its achievements throughout 2025 and its corporate outlook for 2026.
- In 2025, the company received its first cash milestone from the OpRegen® cell therapy collaboration with Roche and Genentech, and successfully completed current Good Manufacturing Practice (cGMP) production runs using its proprietary AlloSCOPE™ manufacturing platform.
- The OpRegen program, currently in a Phase 2a trial for dry age-related macular degeneration (dry-AMD), demonstrated visual improvement lasting at least 3 years in earlier studies, with Genentech expanding clinical sites and receiving RMAT designation.
- For 2026, Lineage plans to provide continued updates on OpRegen, advance its OPC1 program in clinical testing, and expand its manufacturing capabilities, focusing on achieving key clinical and financial milestones.
Jan 5, 2026, 1:00 PM
Lineage Cell Therapeutics Reports Q3 2025 Financial Results and Program Updates
LCTX
Earnings
New Projects/Investments
Product Launch
- Lineage Cell Therapeutics reported $3.7 million in revenues and a cash position of $40.5 million for the third quarter 2025, with cash expected to support operations into Q2 2027.
- The company successfully completed cGMP production runs for its OpRegen and OPC1 programs, capable of producing millions of doses, and is advancing OpRegen cell therapy for age-related macular degeneration under a collaboration with Roche and Genentech.
- Lineage entered a research collaboration with William Demant Invest A/S to fund preclinical development of ReSonance (ANP1) for sensorineural hearing loss and launched a new Type 1 Diabetes cell therapy initiative.
Dec 16, 2025, 4:53 PM
Lineage Cell Therapeutics, Inc. Reports Q3 2025 Financial Results and Business Updates
LCTX
Earnings
New Projects/Investments
Guidance Update
- Lineage Cell Therapeutics, Inc. reported a net loss of $29.8 million, or $0.13 per share, for Q3 2025, primarily driven by a $26.6 million non-cash fair value remeasurement of warrant liabilities.
- Total revenues for Q3 2025 were $3.7 million, with total operating expenses at $7.5 million.
- As of September 30, 2025, the company held $40.5 million in cash, cash equivalents, and marketable securities, which is expected to support planned operations into Q2 2027.
- The company entered a research collaboration with William Demant Invest A/S for its ReSonance (ANP1) program, with WDI contributing up to $12 million for preclinical development.
- Business highlights include positive 36-month results from the RG6501 (OpRegen) Phase 1/2a clinical study and the launch of a new cell therapy initiative (ILT1) for Type 1 Diabetes.
Nov 6, 2025, 9:12 PM
Lineage Cell Therapeutics Reports Q3 2025 Financial Results and Key Business Updates
LCTX
Earnings
Guidance Update
New Projects/Investments
- Lineage Cell Therapeutics reported a net loss of $29.8 million, or $0.13 per share, for the third quarter of 2025, compared to a net loss of $3.0 million, or $0.02 per share, for the same period in 2024, primarily driven by a $26.6 million non-cash quarterly fair value remeasurement of warrant liabilities.
- Total revenues for the three months ended September 30, 2025, were $3.7 million, a slight decrease from $3.8 million in the prior year period, while total operating expenses decreased marginally to $7.5 million from $7.6 million.
- As of September 30, 2025, the company held $40.5 million in cash, cash equivalents, and marketable securities, which is expected to support planned operations into Q2 2027.
- Lineage entered a research collaboration with William Demant Invest A/S, with WDI contributing up to $12 million to fund the preclinical development of the ReSonance (ANP1) program for sensorineural hearing loss.
- Positive 36-month results from the RG6501 (OpRegen) Phase 1/2a Clinical Study were featured, suggesting evidence of sustained gains in visual acuity and structural support of the retina.
Nov 6, 2025, 9:01 PM
Lineage Cell Therapeutics Announces Research Collaboration with William Demant Invest
LCTX
New Projects/Investments
- Lineage Cell Therapeutics, Inc. (LCTX) has entered into a three-year research collaboration agreement with William Demant Invest A/S (WDI).
- The collaboration, announced on August 26, 2025, focuses on advancing the preclinical development of Lineage's auditory neuronal cell transplant, ReSonance (ANP1), for the treatment of hearing loss.
- William Demant Invest will fund up to $12 million in research collaboration costs over the period.
- The main objective of the agreement is to complete a preclinical phase, aiming for readiness to potentially progress to human clinical trials.
Aug 26, 2025, 12:00 AM
Quarterly earnings call transcripts for Lineage Cell Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more